Our mission - is to facilitate the transition of the Russian pharmaceutical market to develop into mature, be a guide on the course of development of the potential of all the pharmaceutical market participants, thereby improving the quality of life for the end user and society in general. Despite the relatively high susceptibility to Russia's external economic and financial risks, imbalances in the domestic policy and great social disparities, the pharmaceutical market in Russia has had a stable positive growth for the last few years.
In 2018, the FDA approved 106 new medical devices with pre-sale permits issued. As noted in the department, this is a record number of approvals of new medical devices for the year. The previous record was set in 2017, when they were registered 98.
For the first 11 months of 2018, ready-made drugs were imported to our country in the amount of 475.3 billion rubles. (in release prices for free circulation with VAT), the ruble dynamics over the same period last year was only + 0.5%. In-bulk production accounts for 97.3 billion rubles, an increase here recorded at + 13.6%. The total volume of drugs imported into our country since the beginning of the year increased in ruble terms by 2.5%.
The government of the Russian Federation approved the Program of state guarantees of free medical care for citizens in 2019 and for the planned period of 2020 and 2021. The relevant decree of the Government of the Russian Federation of 10.12.2018, No. 1506, was signed by Prime Minister Dmitry Medvedev.